A multi-institutional prospective study of lentinan in advanced gastric cancer patients with unresectable and recurrent diseases: effect on prolongation of survival and improvement of quality of life. Kanagawa Lentinan Research Group.

摘要: Background/aims Lentinan is one of the host-mediated anti-cancer drugs which has been shown to affect host defense immune systems. Although mechanisms involved in antitumor effects lentinan have reported experimentally, clinical outcome on prolongation survival and improvement quality life gastric cancer patients with unresectable or recurrent diseases yet be clarified. The aim present study was investigate whether administration prolonged improved these patients. Methodology A multi-institutional randomized prospective protocol, consisting administered tegafur cisplatin (control group), lentinan, (lentinan performed. Quality investigated using a questionnaire survey. Results Median significantly longer group than control (297 days vs. 199 days, p = 0.028). One-year rate greater (49.1% 0%). Total QOL score, especially appetite sleep quality, lentinan. Conclusions considered prolong when are treated combination other chemotherapeutic agents.